Placebo-controlled double-blind comparative study of ME2112 in patients with acute exacerbation of schizophrenia (Phase III)

Trial Profile

Placebo-controlled double-blind comparative study of ME2112 in patients with acute exacerbation of schizophrenia (Phase III)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Meiji Seika Pharma
  • Most Recent Events

    • 10 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top